Cost effectiveness of avacopan for ANCA-associated vasculitis in China

Avacopan-based regimens are cost-effective versus GC-based therapy for GPA/MPA in China and support value-based pricing of $11.12-$12.70 per 10 mg.

Authors

Institutions

Publication Details

Journal
Clinical and Experimental Rheumatology
Published
2025-11-13
DOI
https://doi.org/10.55563/clinexprheumatol/bmn4te
Primary Topic
Vasculitis and related conditions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Cost effectiveness of avacopan for ANCA-associated vasculitis in China

Hanqiao Shao, Weiwei Tang, Yunong Jiang
Clinical and Experimental Rheumatology
Vasculitis and related conditions
article

Cost effectiveness of avacopan for ANCA-associated vasculitis in China

Hanqiao Shao, Weiwei Tang, Yunong Jiang
article en

Abstract

Avacopan-based regimens are cost-effective versus GC-based therapy for GPA/MPA in China and support value-based pricing of $11.12-$12.70 per 10 mg.

Clinical and Experimental Rheumatology
China Pharmaceutical University (CN)
Openalex Percentile: Top 23%
Vasculitis and related conditions
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Cost effectiveness of avacopan for ANCA-associated vasculitis in China — Hanqiao Shao, Weiwei Tang, et al. · Clinical and Experimental Rheumatology (2025) | TGRS Research Map | TGRS